Shibata, Nobuhiro http://orcid.org/0000-0001-8647-5098
Yoshinami, Tetsuhiro
Tamaki, Kentaro
Nukada, Tomoyuki
Ohno, Shinji http://orcid.org/0000-0003-2093-3353
Funding for this research was provided by:
Kyowa Kirin Co., Ltd.
Article History
Received: 21 March 2023
Accepted: 19 June 2023
First Online: 6 July 2023
Declarations
:
: Nobuhiro Shibata reports consulting or advisory roles for Kyowa Kirin Co., Ltd.; has received speaker’s bureau from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., MSD K.K., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., and Becton, Dickinson and Company; and has received research funding from Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and MSD K.K. Tetsuhiro Yoshinami has received speaker honoraria from Kyowa Kirin Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Kentaro Tamaki has no competing interest to declare. Tomoyuki Nukada is an employee of Kyowa Kirin Co., Ltd. Shinji Ohno has received speaker honoraria from Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku Co., Ltd., and Chugai Pharmaceutical Co., Ltd. and received grants from Eisai Co., Ltd.
: The study protocol was approved by the Research Institute of Healthcare Data Science (RI2021015). According to the “Ethical Guidelines for Medical and Health Research Involving Human Subjects”, a study using secondary data stored in an anonymized structured format, such as this study, is outside the scope of the guidelines. Informed consent was not required for this study.
: Not applicable.
: Not applicable.